Solid Biosciences Inc. develops precision genetic medicines for rare neuromuscular and cardiac diseases. The company’s recurring news centers on its gene therapy portfolio, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia, and SGT-601 for TNNT2-mediated dilated cardiomyopathy.
Company updates also cover clinical data from Duchenne studies, regulatory designations for SGT-003, scientific presentations in gene and cell therapy, capital-raising activity, inducement equity grants, investor conference participation, shareholder voting matters, and governance disclosures.
Solid Biosciences (Nasdaq: SLDB) plans to file an Investigational New Drug (IND) application for SGT-003, a gene therapy for Duchenne muscular dystrophy, in the second half of 2023. The company is also transitioning manufacturing processes for its candidates targeting Friedrich's Ataxia and dilated cardiomyopathy. Kevin Tan has been appointed as Chief Financial Officer. Solid reports approximately $214 million in cash, which is expected to fund strategic priorities into 2025. The company aims to advance its gene therapies, focusing on high unmet needs in neuromuscular and cardiac diseases.
On January 6, 2023, Solid Biosciences Inc. (Nasdaq: SLDB) approved inducement awards for new CFO Kevin Tan. The grant includes an option to purchase 90,000 shares and a restricted stock unit for 45,000 shares, aligning with Nasdaq rules. The options have a ten-year term with an exercise price set at $6.00, the closing stock price on January 9, 2023. The vesting schedule is structured to promote retention, with 25% vested after one year and monthly vesting thereafter for the option, while the restricted stock units will vest over four years.
Solid Biosciences Inc. (Nasdaq: SLDB) has appointed Kevin Tan as Chief Financial Officer. With over 20 years of financial experience, Tan's expertise in capital markets and gene therapy is expected to support the company’s growth and pipeline advancement. CEO Bo Cumbo expressed confidence in Tan’s leadership at this pivotal time for the company. Solid continues to focus on developing genetic medicines for neuromuscular and cardiac diseases, aiming to enhance patient outcomes through innovative treatments.
Solid Biosciences Inc. (Nasdaq: SLDB) announced that CEO Bo Cumbo will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 9:00 am PT / 12:00 pm ET. Interested institutional investors can schedule meetings with management through their J.P. Morgan representatives. A live webcast of the presentation will be available on the company's website's Events page, with a replay accessible for 30 days. Solid Biosciences focuses on developing genetic medicines for neuromuscular and cardiac diseases, including programs for Duchenne and Friedreich’s Ataxia.
Solid Biosciences (Nasdaq: SLDB) announced inducement awards for its newly appointed executive team, including President and CEO Bo Cumbo and other key officers. The grants were approved by the board under Nasdaq rules, totaling stock options for 192,833 shares and RSUs for 85,514 shares to 22 new hires. Each award vests over four years, with a ten-year term and an exercise price of $6.77 per share, aligned with the company’s stock price at the time of the awards. This announcement coincided with Solid's acquisition of AavantiBio, emphasizing its commitment to advancing therapies for neuromuscular and cardiac diseases.
Solid Biosciences (Nasdaq: SLDB) has completed its acquisition of AavantiBio, a gene therapy company specializing in neuromuscular and cardiac diseases. The merger creates a new precision genetic medicine entity focused on therapies for Duchenne muscular dystrophy, Friedreich’s ataxia, and other cardiac conditions. The combined company holds approximately $215 million in cash and investments, sufficient to fund operations until 2025. Bo Cumbo will lead the merged company as President and CEO, with a focus on advancing key gene therapy programs.
On December 1, 2022, Solid Biosciences (Nasdaq: SLDB) announced that stockholders approved all proposals at a special meeting. This includes issuing shares of common stock to AavantiBio shareholders as part of a merger agreement dated September 29, 2022, along with a concurrent $75 million private placement. The merger aims to create a focused genetic medicine company targeting neuromuscular and cardiac rare diseases, particularly Duchenne muscular dystrophy. The combined company is expected to advance several key gene therapy programs, including SGT-003 for Duchenne and AVB-202 for Friedreich’s ataxia.
Solid Biosciences Inc. (SLDB) announced participation in the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 10:30 a.m. ET. CEO Ilan Ganot, AavantiBio CEO Bo Cumbo, and CSO Carl Morris will partake in a fireside chat. A live webcast will be accessible on the company's investor relations website with a replay available post-event. Solid Biosciences is dedicated to developing therapies for Duchenne muscular dystrophy and is working on a gene therapy candidate, SGT-003, aimed at addressing the underlying mutation of the disease.
Solid Biosciences (SLDB) recently shared advancements in its gene therapy program for Duchenne muscular dystrophy, focusing on SGT-003, which is set for an Investigational New Drug (IND) submission by mid-2023. The company ended Q3 with $142.2 million in cash, expected to last into Q2 2024. With the planned acquisition of AavantiBio and a $75 million private placement expected by year-end, Solid anticipates a cash reserve of $215 million to support future milestones through 2025.
Solid Biosciences (Nasdaq: SLDB) announced a 1-for-15 reverse stock split effective at 5:00 p.m. ET on October 27, 2022. This action reduces the number of outstanding shares from approximately 113 million to about 7.5 million, aimed at complying with Nasdaq's minimum bid price requirements. Post-split, shares will trade on a split-adjusted basis starting October 28, 2022. The split was approved by shareholders on June 7, 2022, and no fractional shares will be issued; instead, cash payments will be provided for fractional entitlements.